Secukinumab 150mg

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Palmoplantar Pustular PsoriasisPlaque-type Psoriasis

Phase 3

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

CompletedNCT01412944

Novartis PharmaceuticalsPlaque-type Psoriasis

Start: 2011-12-31End: 2013-04-30Updated: 2015-03-18

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

CompletedNCT01636687

Novartis PharmaceuticalsPlaque-type Psoriasis

Start: 2012-10-17End: 2016-10-27Updated: 2018-09-27

Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

CompletedNCT02008890

Novartis PharmaceuticalsPalmoplantar Pustular Psoriasis

Start: 2013-12-26End: 2017-05-31Updated: 2019-01-04

Related Papers

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.

2023-09-2022 citations

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.

2023-06-216 citations

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

Pediatric Drugs2022-06-1317 citations

Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications

Rheumatology and Therapy2022-03-1933 citations

Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab.

2021-06-1010 citations

Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials.

2020-01-034 citations

Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies

Dermatology and Therapy2016-08-3027 citations

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

Dermatology and Therapy2016-08-3017 citations